Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | REV1 | Q9UBZ9 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22722422 | 0.83 | KMT2A (0.60) | POLBMEN1KMT2AHSD17B10LMNA | |
| SCHEMBL20965082 | 0.81 | HPGD (0.64) | POLBMEN1KMT2AHSD17B10LMNA | |
| SCHEMBL1080002 | 0.77 | MEN1 (0.65) | POLBMEN1KMT2AHSD17B10LMNA | |
| SCHEMBL20964672 | 0.75 | MAPT (0.66) | POLBMEN1KMT2AHSD17B10LMNA | |
| SCHEMBL20964788 | 0.74 | ALDH1A1 (0.64) | POLBMEN1KMT2ALMNAMAPT | |
| SCHEMBL6279483 | 0.73 | MEN1 (0.57) | POLBMEN1KMT2AHSD17B10MAPT | |
| SCHEMBL2327539 | 0.70 | ALDH1A1 (0.64) | POLBMEN1KMT2ALMNAMAPT | |
| SCHEMBL791289 | 0.68 | MEN1 (0.71) | MEN1KMT2ALMNAMAPTALDH1A1 | |
| SCHEMBL4005357 | 0.68 | HSD11B1 (0.60) | POLBMEN1KMT2ALMNAMAPT | |
| SCHEMBL21416724 | 0.67 | MEN1 (0.60) | POLBMEN1KMT2AHSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10851096-B2 | Aryl and heteroaryl amides for use as anti-proliferative, anti-thrombotic, and anti-viral agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190127361-A1 | Therapeutic Compounds | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127361-A1 | Therapeutic Compounds | SDHA, SLC10A1, SERPINC1 | POLB 2781/4885MEN1 179/4885KMT2A 4728/4885 |
| US-10851096-B2 | Aryl and heteroaryl amides for use as anti-proliferative, anti-thrombotic, and anti-viral agents | SERPINC1, F12, RPL35 | POLB 298/4885MEN1 2387/4885KMT2A 3241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.